By Connor Hart

Perrigo received notice from the Food and Drug Administration that its infant-formula facility in Wisconsin would be reclassified to "No Action Indicated," the company said.

"This marks a substantial advancement from the facility's 'Voluntary Action Indicated' status existing prior to this 2024 inspection," the maker of over-the-counter pharmaceuticals said Thursday.

A "no action" indication means that no objectionable conditions or practices were found during an inspection, according to the FDA. A "voluntary action" indicated means that objectionable conditions or practices were found, though the agency won't take or recommend any administrative or regulatory action.

The reclassification comes after the FDA inspected the facility in October and November.

Also on Thursday, Perrigo posted a loss of $44.5 million, or 32 cents a share, in the fourth quarter, compared with a loss of $32.3 million, or 24 cents a share, a year earlier.

Adjusted per-share earnings came in at 93 cents, just ahead of the 92 cents that analysts surveyed by FactSet expected.

Net sales slipped 1.6%, to $1.14 billion, below the $1.19 billion that analysts modeled.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

February 27, 2025 18:37 ET (23:37 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.